REVIEW Bevantolol acts as both a beta blocker and a calcium channel blocker for the treatment of angina pectoris and hypertension. It possesses a relatively high degree of antagonistic selectivity for beta 1-adrenoceptors, thereby inhibiting normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure. It is devoid of intrinsic sympathomimetic activity and possesses only weak local anaesthetic properties. Interestingly, bevantolol has been shown to cause a lowering effect on peripheral vascular resistance.
Holmes, Ann; Meyer, Robert Frederick beta-Adrenergic blocking 1-(3,4-dimethoxyphenethylamino)-3-phenoxy-2-propanols Ger. Offen. (1973), DE 2259489 A1 19730705.
Hoefle, Milton L.; Hastings, Stephen G.; Meyer, Robert F.; Corey, Ruth M.; Holmes, Ann; Stratton, Charlotte D. Cardioselective beta-adrenergic blocking agents. 1. 1-[(3,4-Dimethoxyphenethyl)amino]-3-aryloxy-2-propanols Journal of Medicinal Chemistry (1975), 18(2), 148-52.
Hoekstra, Marvin S. 1-(3,4-Dimethoxyphenethylamino)-3-(substituted phenoxy)-2-propanols Eur. Pat. Appl. (1985), EP 165682 A1 19851227.
Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.